The Value of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals

A cost effectiveness analysis, presented at the International Liver Congress held in London, UK on 22-26 June 2022, demonstrated that scaling up testing and treatment with direct-acting antivirals reduces the incidence and prevalence of chronic hepatitis C virus in the Spanish population, providing further evidence that increasing access to testing and treatment may contribute to the global and Spanish public health goal of eliminating HCV and its associated liver-related morbidity and mortality.

More details about the analysis are available here.